Chromatin Remodeling by Transcriptional Activation Domains in a Yeast Episome*

(Received for publication, January 16, 1997, and in revised form, February 20, 1997)

Grace A. Stafford and Randall H. Morse Dagger

From the Molecular Genetics Program, Wadsworth Center, New York State Department of Health and State University of New York School of Public Health, Albany, New York 12201-2002

ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
FOOTNOTES
ACKNOWLEDGEMENTS
REFERENCES


ABSTRACT

We examine the generality of transcription factor-mediated chromatin remodeling by monitoring changes in chromatin structure in a yeast (Saccharomyces cerevisiae) episome outside of the context of a natural promoter. The episome has a well defined chromatin structure and a binding site for the transcription factor GAL4 but lacks a nearby functional TATA element or transcription start site, so that changes in chromatin structure are unlikely to be caused by transcription. To separate changes caused by binding and by activation domains, we use both GAL4 and a chimeric, hormone-dependent activator consisting of the GAL4 DNA-binding domain, an estrogen receptor (ER) hormone-binding domain, and a VP16 activation domain (Louvion, J.-F., Havaux-Copf, B. and Picard, D. (1993) Gene (Amst.) 131, 129-134). Both GAL4 and GAL4·ER·VP16 show very little perturbation of chromatin structure in their nonactivating configurations. Substantial additional perturbation occurs upon activation. This additional perturbation is marked by changes in micrococcal nuclease cleavage patterns, restriction endonuclease accessibility, and DNA topology and is not seen with the nonactivating derivative GAL4·ER. Remodeling by GAL4·ER·VP16 is detectable within 15 min following hormone addition and is complete within 45 min, suggesting that replication is not required. We conclude that activation domains can exert a major influence on chromatin remodeling by increasing binding affinity and/or by recruitment of other chromatin remodeling activities and that this remodeling can occur outside the context of a bona fide promoter.


INTRODUCTION

Transcriptional induction in eukaryotes requires binding of activators to promoter elements termed enhancers (called upstream activator sequences (UASs)1 in yeast). Binding of a transcriptional activator in its activating form results in recruitment or reconfiguration of a preinitiation complex in a form competent to allow initiation and elongation by RNA polymerase II. These events occur in the context of chromatin, which means that histone proteins are available to compete with activators and components of the preinitiation complex for binding to DNA. One function of transcriptional activators may be to help overcome nucleosomal repression of transcription, particularly at the site of preinitiation complex formation (1).

Gene activation is often accompanied by perturbations in chromatin structure. For some genes, this perturbation appears to be essential for proper transcriptional regulation (2-4). In some instances, specific effects of activation domains have been observed. The yeast activator GAL4 can bind to promoter sites in both activating and nonactivating forms; this has allowed the detection of subtle effects on chromatin structure in the GAL1-10 promoter that require an unmasked activation domain (2, 5-6). Another transcriptional activator, PHO4, perturbs chromatin structure at the PHO5 promoter in an activation domain-dependent manner (7). The thyroid hormone receptor-retinoid X receptor heterodimer binds without perturbing chromatin structure in its unliganded state; the addition of hormone results in a local perturbation of chromatin structure in the TRbeta A gene promoter (8).

The above examples of chromatin remodeling by transcription factors occur at natural promoters. Although chromatin remodeling under activating conditions can occur in nonfunctional promoters having mutated TATA boxes (3, 9), other cis-acting promoter elements could still be involved in this process. Perturbation of a positioned nucleosome by GAL4 has been examined outside of the context of a natural promoter in a plasmid episome in yeast (10). In this study, the GAL4 site was near the center of a positioned nucleosome (when GAL4 was absent); GAL4 expression resulted in micrococcal nuclease (MNase) cleavage sites, indicative of nucleosome perturbation. This perturbation appeared stronger, as assessed by the intensities of the MNase cleavages, under activating conditions.

The mechanism by which an activation domain causes chromatin remodeling remains unknown. To examine the generality of transcription factor-mediated chromatin remodeling and to increase our understanding of this important step in transcriptional activation, we have examined the ability of GAL4 and a chimeric activator, GAL4·ER·VP16, to perturb chromatin structure in the yeast episome TALS, which has an exceptionally well defined chromatin structure. In yeast haploid alpha  cells, the repressor complex alpha 2·MCM1 helps to incorporate TALS into strongly positioned nucleosomes (11). One of these nucleosomes contains a GAL4 binding site, which derives from the GAL3 promoter (12). We show that both GAL4 and GAL4·ER·VP16 perturb TALS chromatin most strongly in their activating configurations, and we discuss possible mechanisms by which an unmasked transcriptional activation domain could remodel chromatin in vivo.


EXPERIMENTAL PROCEDURES

Plasmids

Introduction of TA17Delta 80 into yeast has been described (10). TALS (11) and TALS4 (13), in which the UASGAL has been removed by mutagenesis (generous gift of M. Kladde), were excised from pUC19 sequences by digestion with HindIII and religated before introduction into yeast. GAL4·ER·VP16 was expressed from the plasmid pHCA, here referred to as pRS313GAL4·ER·VP16 (Ref. 14; generously provided by D. Picard) or from pRS416GAL4·ER·VP16, which was constructed by ligation of the ClaI-SpeI fragment encompassing the GAL4·ER·VP16 gene from pRS313GAL4·ER·VP16 into pRS416 (Ref. 15). The expression vector for GAL4·ER was constructed by deletion of the SacI fragment bearing the VP16 coding sequence from the expression vector for GAL4·ER·VP16. For experiments in which perturbation of chromatin by GAL4 was monitored, yeast cells contained the multicopy GAL4 expression vector pRS425GAL4 (10). The plasmid pCL1 (16) was used to express GAL4 from the ADH1 promoter. The reporter construct used for beta -galactosidase assays was pRS314-17Delta 80lacZ (10).

Yeast Transformations, Cell Growth, and beta -Galactosidase Assays

Plasmids were transformed into yeast cells (strain YNN282 (MATalpha trp1-Delta his3-Delta 200 ura3-52 lys-801a ade2-10) (11), strain FY24 (MATalpha ura 3-52 trp1Delta 63 leu 2Delta 1) (17), or the gal80- strain KY243 (MATalpha gal80Delta his4-917delta lys2-173R2 leu2Delta 1 ura3-52 trp1Delta 63); generous gift of Karen Arndt) by a modification (18) of the method of Ito et al. (19). Cells were grown in dropout media (Bio 101) in the presence of 2% glucose, 1.5% raffinose, or 2% galactose. beta -Estradiol (Sigma) was added from a 5 mM stock in ethanol to 0.1 µM 3-4 h before harvesting cells or assaying for beta -galactosidase activity. beta -Galactosidase activity was assayed as described (20, 21), and units were expressed as 1000 × A420/(A600 × time (min) × volume (ml)).

Analysis of Plasmid Chromatin

Yeast cells (0.4-1.0 liter) were grown at 30 °C to an optical density at 600 nm between 0.6 and 1.6. Yeast nuclei (22) or spheroplast lysates (23) were prepared and digested as described previously with micrococcal nuclease for 10 min at 37 °C at concentrations varying from 0 to 50 units/ml. Cleavage patterns did not vary within this range of concentrations. For SstI digestion, the same buffer was used with the addition of <FR><NU>1</NU><DE>10</DE></FR> volume of 10 × enzyme buffer supplied by the manufacturer. Control samples were incubated for 30 min without enzyme; these did not show the specific SstI cleavage seen when enzyme was added. TALS chromatin prepared under identical conditions from FY24 and YNN282 strains showed identical MNase cleavage patterns and topoisomer distributions. For digestion of naked DNA, samples were first treated with proteinase K, extracted with phenol and chloroform, and then taken up in 300 µl of 150 mM NaCl, 5 mM KCl, 1 mM EDTA, 20 mM Tris·HCl, pH 8.0, 2 mM CaCl2, 5 mM MgCl2, or in 10 mM HEPES, pH 7.5, 2 mM CaCl2, 5 mM MgCl2 and digested as above. Digestions were stopped by the addition of 55 µl of 5% SDS, 5 mg/ml proteinase K to 300-µl reactions, and after >2 h at 37 °C, samples were extracted with phenol and chloroform and the DNA was precipitated. Pellets were taken up in 100 µl of 10 mM Tris·HCl, pH 8.0, 1 mM EDTA, and treated with RNase A (40 µg); samples from spheroplast lysates were cleaned over 1-ml G50 spin columns (24). For analysis of micrococcal nuclease cleavage patterns by indirect end labeling (25, 26), aliquots of 25-40 µl were digested with EcoRV for 3-4 h, and the DNA was precipitated and then electrophoresed on 1.2% agarose gels at 4 V/cm for 5-6 h. SstI-cut samples were analyzed similarly but on smaller gels run for shorter times. Bromphenol blue was omitted from sample buffers. DNA was transferred to nylon membranes (Duralon UV; Stratagene) by capillary action and hybridized with random primer-labeled probes as described (24). Hybridization and washing were as described (27). Probes used were the 200-bp EcoRV-XbaI fragment (see Figs. 2, 3, 5, and 6) and the 231-bp EcoRV-HindIII fragment (Fig. 1) from TRP1ARS1 or identical fragments prepared by polymerase chain reaction. Marker lanes contained 0.5 ng of a Phi X/HaeIII digest, and labeled Phi X/HaeIII DNA was included with the hybridization probe. Chromatin was prepared from at least two independent clones for all MNase analyses in at least three independent preparations (total). SstI digestion experiments were done with at least three independent chromatin preparations for all conditions examined.


Fig. 2. Nucleosome perturbation in the yeast episome TALS by ligand-activated and nonactivated GAL4·ER·VP16 and by GAL4 in galactose. Nuclei were prepared from yeast cells harboring TALS and pRS313GAL4·ER·VP16 (strain YNN282, lanes 1-8) or TALS and pRS425GAL4 (strain FY24, lanes 9 and 10) and digested with micrococcal nuclease at 0 (lanes 1 and 8), 5 (lanes 2 and 7), 20 (lanes 3, 6, 9, and 10), or 50 units/ml (lanes 4 and 5). Naked DNA was isolated from FY24 cells harboring TALS and digested at 10 units/ml MNase. MNase cleavage sites were mapped counterclockwise relative to the EcoRV site as indicated. The marker lane (M) contains a Phi X/HaeIII digest. The arrowhead indicates a cleavage site that is not cut in cells lacking GAL4·ER·VP16 and grown in glucose (compare lane 9) and that is cut more strongly in cells containing GAL4·ER·VP16 when hormone is present than when it is absent, and the filled circle indicates a cleavage site only cut in the presence of GAL4·ER·VP16 plus hormone or in cells grown in galactose (lane 10). The band marked by an asterisk corresponds to supercoiled plasmid not cut by EcoRV. Location of nucleosomes II-V in cells grown in glucose medium (ellipses) and the alpha 2·MCM1 operator (rectangle between nucleosomes IV and V) are indicated to the left; only nucleosome IV is shown on the plasmid map at the top. The rectangle in nucleosome IV represents the GAL4 binding site.
[View Larger Version of this Image (73K GIF file)]



Fig. 3. Nucleosome perturbation in the yeast episome TALS by GAL4 under activating and nonactivating conditions. Yeast cells (strain YNN282, lanes 1-3, or strain FY24, lanes 4-7) harboring TALS and pRS425GAL4 (lanes 4-5) or pCL1, which constitutively expresses GAL4 from the ADH1 promoter (lanes 6-7) were grown in medium containing glucose, raffinose, or galactose as indicated, and micrococcal nuclease cleavage sites in TALS chromatin were mapped relative to the EcoRV site as indicated using 2 (lanes 5 and 6), 5 (lanes 4 and 7), or 20 units/ml MNase (lanes 1-3). The locations of nucleosomes III-V in cells grown in glucose medium (ellipses) and the alpha 2·MCM1 operator (rectangle between nucleosomes IV and V) are indicated on the sides; only nucleosome IV is shown on the plasmid map at the top. The rectangle in nucleosome IV represents the GAL4 binding site. The filled circles indicate cleavage sites cut more strongly in raffinose than glucose and more strongly in galactose than raffinose.
[View Larger Version of this Image (42K GIF file)]



Fig. 5. Increased accessibility of SstI to nucleosome IV in TALS by binding of GAL4 or GAL4·ER·VP16 in their activating configurations. Nuclei were prepared from yeast cells (strain YNN282) harboring TALS alone, TALS and pRS313GAL4·ER·VP16, or pRS313GAL4·ER as indicated. Nuclei were digested for 15 or 30 min with SstI, and the purified DNA was secondarily digested with EcoRV and then analyzed by indirect end-labeling. The band labeled Parent corresponds to TALS cut only with EcoRV, and the SstI-cut band is also indicated. The bands indicated by the arrowhead (lanes 1, 2, and 5) correspond to supercoiled DNA present because of incomplete digestion by EcoRV, and the filled circles in lane 13 indicate bands due to a naked control plasmid added at 15 min to this sample; the upper band is uncut, and the lower band is cut by SstI. The marker lane (M) contains a Phi X/HaeIII digest.
[View Larger Version of this Image (46K GIF file)]



Fig. 6. No nucleosome perturbation in the yeast episome TALS by beta -estradiol addition in the presence of GAL4·ER. Upper panel, nuclei were prepared from yeast cells (strain YNN282) harboring TALS and pRS313GAL4·ER·VP16 or pRS313GAL4·ER in the presence or absence of beta -estradiol as indicated and digested with micrococcal nuclease at 0 (lanes 2, 7, 8, and 13), 4 (lane 1, which is a naked DNA digest), 5 (lanes 3, 6, 9, and 12), or 20 units/ml (lanes 4, 5, 10, and 11). MNase cleavage sites were mapped counterclockwise relative to the EcoRV site as indicated. Arrowheads indicated cleavages enhanced by hormone addition in the presence of GAL4·ER·VP16. Location of nucleosomes II-V in unperturbed TALS chromatin (ellipses) and the alpha 2·MCM1 operator (rectangle between nucleosomes IV and V) are indicated to the left; only nucleosome IV is shown on the plasmid map at the top. The rectangle in nucleosome IV represents the GAL4 binding site. Lower panel, densitometric scans of lanes 3 and 5 (labeled -E2 and +E2, respectively). The peaks indicated by the arrowhead are enhanced in the presence of hormone and correspond to the bands marked by arrowheads in the upper panel; the left peak (upper band in the upper panel) is more clearly resolved in gels that have been electrophoresed for longer times. Nucleosomes III and IV, the GAL4 binding site in nucleosome IV, and the alpha 2·MCM1 operator (hatched rectangle) are also indicated.
[View Larger Version of this Image (36K GIF file)]



Fig. 1.

Nucleosome perturbation in the yeast episome TA17Delta 80 by ligand-activated and nonactivated GAL4 ER·VP16. Upper panel, nuclei were prepared from yeast cells (strain FY24) harboring TA17Delta 80 and either pRS425GAL4 (left part, lanes 1-4) or pRS416GAL4·ER·VP16 (right part, lanes 5-9) and digested with micrococcal nuclease. Cells were grown in glucose (lanes 1-2 and 5-9) or galactose (lanes 3-4) in the absence (lanes 1-7) or presence (lanes 8-9) of beta -estradiol, as indicated. Micrococcal nuclease cleavage sites were mapped clockwise relative to the EcoRV site as indicated. Samples were digested with increasing amounts of micrococcal nuclease from the outer lanes of each panel toward the centers. Bands indicated by stars are cleaved in naked DNA (data not shown and Ref. 10) and protected by nucleosomes I and II (lanes 1 and 2); the filled stars correspond to bands that are cleaved more strongly than the empty star. Cleavage at these sites indicates that nucleosome positioning has been perturbed. The cleavage site corresponding to the distal border of nucleosome II is marked with a filled circle. Locations of nucleosomes I and II in cells grown in glucose are indicated; the box attached to nucleosome I represents the GAL4 binding site. Lane 8 was taken from a different exposure than lanes 5-7 and 9. Lower panel, densitometric scans of the salient regions of lanes 1 and 4 (upper traces, labeled glucose and galactose, respectively) and lanes 7 and 8 (lower traces, labeled -E2 and +E2, respectively). The filled circle and starred peaks correspond to those in the upper panel, and the regions corresponding to nucleosomes I and II are indicated; the black box attached to nucleosome I represents the GAL4 binding site.


[View Larger Version of this Image (27K GIF file)]


Topoisomer Analysis

DNA was prepared from at least three independent clones for topoisomer analysis as described (28) from 10-ml cultures grown to an A600 of 0.6-1.2 by rapid glass bead lysis. Purified DNA was electrophoresed on 1.5% agarose gels containing 40 µg/ml chloroquine diphosphate (Sigma) at 2 V/cm for 18-20 h, transferred to nylon membranes, and hybridized using probes specific for TRP1ARS1 sequences as described above. Gaussian centers of the topoisomer distributions were calculated as described previously (28), using images scanned on a Molecular Dynamics PhosphorImager.


RESULTS

Chromatin Perturbation by Activating and Nonactivating GAL4·ER·VP16 and GAL4 Assessed by Micrococcal Nuclease Cleavage

Previously we showed that GAL4 can bind to a nucleosomal recognition site in yeast (10). Although this result shows that GAL4 can outcompete histones for occupancy of its site in vivo, it was not determined whether binding could take place to a stable, fully assembled nucleosome or whether it occurred during replication, when nucleosome structure is transiently perturbed. To attempt to address this question, we obtained an expression vector for the chimeric protein GAL4·ER·VP16, which consists of the GAL4 DNA-binding domain, the human estrogen receptor hormone-binding domain, and the viral VP16 activation domain (Ref. 14; generously provided by Dr. D. Picard). This protein, when expressed in yeast, activates transcription from promoters having a GAL4 site or sites in a strictly hormone-dependent fashion (Ref. 14; Table I). We hoped that the GAL4·ER·VP16 protein might also bind DNA in a hormone-dependent manner, so that we could examine its binding to sites in chromatin at various points in the cell cycle.

Table I.

Transcriptional activation by GAL4 and GAL4·ER·VP16

Yeast cells (strain YNN282) harboring a lacZ reporter gene with a single GAL4 binding site in the promoter (314-17Delta 80lacZ; Ref. 10) were grown in the presence or absence of GAL4·ER·VP16, with or without 0.1 µM beta -estradiol, in glucose or galactose, as indicated, and assayed for beta -galactosidase activity. The numbers in parentheses indicate the number of independent measurements for each value.


GAL4·ER·VP16  beta -estradiol Carbon source Activity

Miller units
 -  - Glucose 7  ± 2 (5)
 - + Glucose 7  ± 2 (5)
+  - Glucose 16  ± 9 (7)
+ + Glucose 535  ± 110 (7)
 -  - Galactose 800  ± 60 (8)
 - + Galactose 770  ± 95 (8)
+  - Galactose 345  ± 25 (6)

To determine whether GAL4·ER·VP16 binds to chromatin in vivo in the absence of hormone, we compared transcriptional activation of a UASGAL-lacZ reporter by GAL4 in the presence and absence of the GAL4·ER·VP16 expression vector. beta -Galactosidase activity induced by GAL4 (via growth of cells in galactose) was decreased in the presence of GAL4·ER·VP16 (Table I), suggesting that GAL4·ER·VP16 could compete with GAL4 for site occupancy in the absence of hormone. To determine whether GAL4·ER·VP16 could bind to a nucleosomal site in the absence of hormone, we examined its effect on the chromatin structure of TA17Delta 80 (10). TA17Delta 80 is a TRP1ARS1-based plasmid in which a single strong GAL4 binding site has been introduced such that the site is incorporated near the center (i.e. near the pseudodyad) of a positioned nucleosome in cells grown in glucose, conditions under which GAL4 is expressed at extremely low levels (29). Yeast cells harboring TA17Delta 80 were grown in the presence of GAL4·ER·VP16 with and without hormone and in the absence of GAL4·ER·VP16 in glucose (GAL4 nearly absent) and in galactose (GAL4 present in its activating configuration). Nuclei were prepared and treated with micrococcal nuclease (MNase), and the cleavage sites were mapped relative to an EcoRV restriction site (25, 26). Regions of about 150 base pairs that are protected from MNase digestion in chromatin but are cleaved as naked DNA are diagnostic of positioned nucleosomes (30, 31); in the case of TA17Delta 80 and its progenitor TRP1ARS1, the assignment of positioned nucleosomes I and II (Fig. 1) is also based on a substantial body of earlier work (10, 30, 31).

In cells grown in glucose without the GAL4·ER·VP16 expression vector, GAL4·ER·VP16 is absent and GAL4 is expressed at very low levels, and positioned nucleosomes are present as expected (Fig. 1, lanes 1 and 2). In galactose medium, GAL4 expression is induced, and MNase cleavage sites are generated in the regions of both nucleosomes I and II, as observed previously (Fig. 1, lanes 3-4; Ref. 10). These new cleavages are also seen in naked DNA treated with MNase (10) and indicate that GAL4 is binding to its site and perturbing nucleosome positioning. The same cleavage sites are seen, albeit more weakly, when GAL4·ER·VP16 is expressed in cells grown in glucose medium and hormone is not added (Fig. 1, lanes 5-7), indicating that GAL4·ER·VP16 can bind under nonactivating conditions. Interestingly, the addition of 0.1 µM beta -estradiol caused enhanced cleavage in the regions of nucleosomes I and II in TA17Delta 80 (compare the relative intensities of cleavage sites marked by stars with the site marked by a filled circle, lanes 5-9), suggesting that binding of GAL4·ER·VP16 was increased or altered by the addition of hormone.

These results are consistent with previous findings that binding of GAL4 to TA17Delta 80 under activating conditions (in galactose) allowed strong MNase cleavage in the regions of nucleosomes I and II, whereas ectopic expression of GAL4 in glucose, in which it is repressed by GAL80, or expression of the very weakly activating derivative, GAL4(1-147)H, allowed only weak MNase cleavage (10). We wondered whether a GAL4 binding site embedded in chromatin in a different context would show a similar effect of an unmasked activation domain, so we examined another yeast episome having a GAL4 binding site in a positioned nucleosome, TALS. The TALS episome is packaged into strongly positioned nucleosomes in yeast alpha  cells by the alpha 2·MCM1 complex in conjunction with SSN6 and TUP1 (Refs. 11 and 32; see Fig. 2). Nucleosome IV of TALS, immediately adjacent to the alpha 2·MCM1 operator, contains a strong binding site for GAL4, which derives from the GAL3 promoter (12) and is in a region of nucleosome IV inaccessible to Escherichia coli Dam methyltransferase expressed in yeast (33). As in TA17Delta 80, the GAL4 binding site in this plasmid is removed from its natural context (because the 3' portion of the GAL3 promoter, including the TATA box, is not present in TALS, and sequences farther than 60 base pairs upstream of the UASGAL do not contribute to GAL3 expression (12)). Nearly the entire TALS plasmid is packaged into strongly positioned nucleosomes in yeast alpha  cells, so we thought it would provide a potentially interesting template to examine the effects of GAL4 binding and activation domain unmasking on chromatin structure.

Nuclei from yeast cells harboring TALS were prepared and digested with MNase, and cleavage sites were mapped counterclockwise from the EcoRV site (Fig. 2). Comparison of the digestion patterns of chromatin from cells lacking the GAL4·ER·VP16 expression vector and grown in glucose (lane 9) with naked DNA (lane 11) shows that TALS is packaged into strongly positioned nucleosomes, as observed previously (11). (Although the sample in lane 9 is heavily digested, the cleavage sites are identical to those seen in lighter digests (Ref. 11 and data not shown).) When GAL4·ER·VP16 is expressed, a new cleavage site is generated in the region of nucleosome IV, close to the GAL4 binding site, suggesting that GAL4·ER·VP16 can bind and perturb nucleosome positioning in TALS even in its nonactivating form (Fig. 2, lanes 2-4; see the band marked by an arrowhead, which is absent from lane 9). A parallel culture incubated for 4 hours in the presence of 0.1 µM beta -estradiol showed further changes in chromatin structure (Fig. 2, lanes 5-7); the cleavage indicated by the arrowhead is enhanced relative to the site below it, and a new site is generated in the vicinity of nucleosome III (filled circle). A weak cleavage site is also generated near the center of the region protected by nucleosome IV, which is also cut only weakly in naked DNA (lane 11).

GAL4 in galactose perturbs the MNase cleavage pattern of TALS chromatin similarly to GAL4·ER·VP16 in the presence of hormone. GAL4 can also bind to DNA in a nonactivating configuration in the absence of galactose, when its activation domain is masked by the repressor protein GAL80 (34, 35). Binding of nonactivating GAL4 in vivo has been detected by dimethyl sulfate footprinting (36), photofootprinting (37), and perturbation of positioned nucleosomes (10). When galactose is present, a conformational change unmasks the GAL4 activation domain (38). To determine whether GAL4, like GAL4·ER· VP16, would perturb TALS chromatin differently in its activating and nonactivating configurations, we performed MNase digests of TALS chromatin from cells grown in glucose (GAL4 nearly absent), raffinose (GAL4 present in its nonactivating configuration), and galactose (GAL4 present in its activating configuration). We also analyzed chromatin from cells in which GAL4 was ectopically expressed from the strong ADH1 promoter in glucose. The high levels of GAL4 expressed from the ADH1 promoter titrate GAL80 (35), but most (>75%; data not shown) of the GAL4 molecules are still repressed by GAL80 under these conditions.

Fig. 3 shows changes in the MNase cleavage pattern of TALS in galactose compared with glucose (lanes 2 and 3; see bands marked by dots) which are similar to those seen in the presence of ligand-activated GAL4·ER·VP16 compared with in its absence (Fig. 2, compare lanes 5-7 with lane 9; see bands marked by arrowhead and dot). When GAL4 is expressed in its nonactivating configuration by growth of cells in raffinose (Fig. 3, lane 1) or under conditions where activation is weak by ectopic expression in glucose (lanes 6 and 7), the MNase cleavage pattern appears intermediate between that seen in glucose and galactose. Thus, similar to what was observed for GAL4·ER· VP16, binding of GAL4 and unmasking of its activation domain have distinct effects on the MNase cleavage pattern of TALS chromatin.

Topological Perturbation of TALS by Activating and Nonactivating GAL4 and GAL4·ER·VP16

Close comparison of the MNase cleavage patterns of naked TALS DNA and of TALS chromatin in the presence of hormone-activated GAL4·ER· VP16 (Fig. 2, lanes 5-7 versus lane 11) suggests that nucleosome IV may be lost entirely, since the cleavage pattern in this region is very similar to that of naked DNA. A new MNase cleavage site is also generated in the vicinity of nucleosome III upon hormone administration (Fig. 2, lanes 5-7 versus lanes 2-4, filled circle), but this site is close to the edge of nucleosome III, and its cleavage may reflect only a subtle change in nucleosome positioning. To examine the extent of nucleosome loss from TALS caused by binding of activated GAL4·ER·VP16, we measured plasmid topology of TALS isolated from cells harboring GAL4·ER·VP16 in the presence and absence of beta -estradiol. Since each nucleosome introduces one negative supercoil into plasmid DNA (39, 40), any loss of nucleosomes accompanying binding of GAL4·ER·VP16 in either its activating or nonactivating forms should change plasmid topology.

DNA was rapidly isolated from yeast cells harboring TALS under conditions that rapidly inactivate topoisomerase, so plasmid topology reflects that present in vivo (28, 41, 42). Samples were electrophoresed on chloroquine-containing gels to resolve individual topoisomers, blotted, and hybridized with a probe specific for TALS. Under the conditions used (40 µg/ml chloroquine diphosphate), TALS topoisomers migrated as positively supercoiled molecules, so that faster migrating bands represent more positively supercoiled species. Fig. 4 shows that in the absence of GAL4·ER·VP16, administration of 0.1 µM beta -estradiol had no effect on TALS topology (lanes 1 and 2). Expression of GAL4·ER·VP16 in the absence of hormone had no effect on TALS topology (lane 3), despite its effect on the MNase cleavage pattern (Fig. 2, lanes 2-4 compared with lane 9). Hormone administration caused a loss of nearly one negative supercoil (Fig. 4, lane 4; Table II), suggesting loss of one nucleosome in a majority of the TALS minichromosomes. Similarly, growth in raffinose, in which GAL4 is expressed but does not activate transcription due to its repression by GAL80, resulted in minimal topological perturbation (compare lane 5 with lane 1), whereas growth in galactose, where GAL4 is present in its activating form, caused a loss of nearly one negative supercoil (lane 6). When the same experiment was done in a gal80- strain, loss of negative supercoiling was seen in cells grown in raffinose compared with cells grown in glucose, and no change was seen between cells grown in raffinose and galactose (data not shown). GAL4 expressed ectopically in glucose medium, in which it is repressed by GAL80, had only a minimal effect on TALS topology, as did the very weakly activating derivative GAL4(1-147)H, which lacks the GAL4 activation domain (data not shown). A derivative of TALS lacking the GAL4 binding site, TALS4, showed no topological shift between glucose and galactose (Fig. 4, lanes 9 and 10) and was not affected by hormone addition in the presence of GAL4·ER·VP16 (data not shown). Results from several such experiments are tabulated in Table II, providing quantitative support for the visual evidence of Fig. 4.


Fig. 4. Topological perturbation of TALS chromatin. DNA was isolated from yeast cells (strain YNN282, lanes 1-4, 7, and 8; strain FY24, lanes 5, 6, 9, and 10) harboring TALS alone (lanes 1, 2, 5, and 6), TALS4 alone (lanes 9 and 10), TALS and pRS313GAL4·ER·VP16 (lanes 3 and 4), or TALS and pRS313GAL4·ER (lanes 7 and 8). Cells were grown in glucose, raffinose, or galactose with or without beta -estradiol, as indicated (lanes 9 and 10 were grown without beta -estradiol). Topoisomers were resolved on gels containing 40 µg/ml chloroquine and visualized by blotting with a TALS-specific probe. The uppermost band in each lane is the nicked circular plasmid, and the bands below correspond to individual topoisomers with more rapidly migrating bands being more positively supercoiled. The gaussian centers of the distributions are indicated by filled circles.
[View Larger Version of this Image (59K GIF file)]


Table II.

Alterations in linking number of TALS minichromosomes upon binding or activation of GAL4 or GAL4·ER·VP16

Values shown were obtained by taking the differences between the centers of the Gaussian distribution of topoisomers under the conditions indicated for each column. For instance, the average linking number in the presence of GAL4·ER·VP16 was increased by 0.7 turns when beta -estradiol was present compared with when it was absent (column 2). The numbers in parentheses indicate the number of independent measurements for each value.


Activator
GAL4·ER·VP16 GAL4·ER·VP16±E2a GAL4: glu/raffb GAL4: glu/galb

Linking number shift 0.0  ± 0.2 (3) 0.7  ± 0.1 (4) 0.24  ± 0.15 (5) 0.7  ± 0.2 (4)

a E2, 0.1 µM beta -estradiol.
b Cells were grown in glucose (no GAL4), raffinose (GAL4 expressed but repressed by GAL80), or galactose (GAL4 expressed and activation-competent).

Restriction Enzyme Accessibility Modulated by Binding of Activating and Nonactivating GAL4 and GAL4·ER·VP16

If nucleosome IV of TALS is lost from a majority of minichromosomes upon binding of GAL4·ER·VP16 in the presence of beta -estradiol, but only from a minority in the absence of hormone, we would expect restriction endonuclease sites in this region to be only moderately more accessible in the presence of GAL4·ER·VP16 without hormone than in its absence and considerably more accessible following hormone addition. We have used an SstI site that is close to the center of the region protected by nucleosome IV to test this hypothesis. Yeast nuclei from cells harboring TALS were treated with SstI, and aliquots were stopped after 15- and 30-min incubation with enzyme. Cleavage of the nucleosome IV SstI site was increased only slightly after 30 min compared with after 15 min (Fig. 5), and a control plasmid with an SstI site added at 15 min was nearly completely cleaved by 30 min, demonstrating that SstI activity was not lost during the incubation (Fig. 5, lane 13 and data not shown). Together these results suggest that almost all of the accessible SstI sites in the TALS minichromosomes were cleaved by the end of the 30-min reaction.

TALS minichromosomes from cells grown in glucose and lacking GAL4·ER·VP16 were cleaved very little by SstI (Fig. 5, lanes 10 and 11). Cleavage was increased little if at all by expression of GAL4·ER·VP16 (lanes 1 and 2) but was increased substantially and reproducibly by incubation with beta -estradiol (lanes 4 and 5). Similarly, expression of GAL4 under nonactivating conditions by growth of cells in raffinose caused a very modest increase in SstI accessibility (Fig. 5, lanes 12 and 13), whereas expression of the activating form of GAL4 by growth in galactose consistently increased accessibility (Fig. 5, lanes 14 and 15). Thus, restriction enzyme accessibility is consistent with increased disruption of nucleosome IV accompanying unmasking of the activation domains of GAL4 or GAL4·ER·VP16.

Effect of the Activation Domain on Hormone-dependent Perturbation of TALS Chromatin by GAL4·ER·VP16

The data presented so far suggest that the activation domains of GAL4 and GAL4·ER·VP16 affect their interaction with TALS chromatin. However, it has been reported that DNA binding of intact ER and derivatives is affected by hormone addition (13, 43, 44). To separate effects exerted by the hormone-binding domain of GAL4·ER·VP16 on the DNA-binding domain from those due to unmasking of the activation domain, we decided to examine the effect of eliminating the activation potential of GAL4·ER·VP16. We therefore excised the VP16 coding region from our expression vector to create an expression vector for GAL4·ER. GAL4·ER is unable to activate transcription from the simple UASGAL-lacZ reporter used in our assay (Table III), in agreement with Louvion et al. (14). It does, however, measurably inhibit transcription of the UASGAL-lacZ reporter by GAL4 (Table III), suggesting that it is expressed at levels similar to that of GAL4·ER·VP16. GAL4·ER slightly affects TALS chromatin in the absence of hormone, as assayed by micrococcal nuclease digestion (Fig. 6, lanes 9 and 10; compare with Fig. 2, lane 9, and Fig. 3, lane 3), similar to what was observed for GAL4·ER·VP16 (Fig. 2). However, in contrast to GAL4·ER· VP16, hormone addition in the presence of GAL4·ER does not further perturb the MNase cleavage pattern (Fig. 6, lanes 9-12 versus lanes 3-6). Consistent with this lack of effect, hormone addition does not alter supercoiling (Fig. 4, lanes 7-8) or appreciably increase restriction enzyme accessibility (Fig. 5, lanes 6-9). We conclude that it is not a hormone-induced conformational change in GAL4·ER·VP16 per se but unmasking of the VP16 activation domain upon ligand binding by the ER hormone binding domain that results in chromatin perturbation.

Table III.

GAL4·ER is transcriptionally inactive

Yeast cells (strain YNN282) harboring a lacZ reporter gene with a single GAL4 binding site in the promoter (314-17Delta 80lacZ; Ref. 10) were grown in the presence or absence of GAL4·ER with or without 0.1 µM beta -estradiol, in glucose or galactose, as indicated, and assayed for beta -galactosidase activity. The numbers in parentheses indicate the number of independent measurements for each value.


GAL4·ER ±beta -estradiol Carbon source Activity

Miller units
Present  - Glucose 9  ± 1 (4)
Present + Glucose 10  ± 1 (4)
Present  - Galactose 315  ± 40 (8)
Absent + Galactose 770  ± 95 (8)

Kinetics of Chromatin Remodeling by GAL4·ER·VP16

The topological analysis presented above entails rapid isolation of DNA from small (10-ml) volumes of yeast cells. We took advantage of this protocol to examine the kinetics of TALS chromatin remodeling by GAL4·ER·VP16 following hormone administration. Yeast cells harboring TALS and the expression vector for GAL4·ER·VP16 were grown, and DNA was isolated from 10- or 20-ml aliquots immediately before (t = 0) and at intervals following the addition of beta -estradiol to 0.1 µM. Topological distributions of TALS from one representative experiment are shown in Fig. 7A, and results from three independent experiments are combined graphically in Fig. 7B. A substantial change in TALS topology is seen 15 min after hormone addition, and the topological shift is essentially complete after 30 min. Since the cell doubling time under the experimental conditions used was more than 2 h, we conclude that replication is not required for chromatin remodeling by GAL4·ER·VP16 in yeast.


Fig. 7. Time course of topological change in TALS following hormone addition in the presence of GAL4·ER·VP16. A, yeast cells harboring TALS and expressing GAL4·ER·VP16 were grown and DNA isolated before (t = 0) or at various intervals after the addition of beta -estradiol to 0.1 µM. Topoisomers were resolved by electrophoresis on 1.5% agarose gels containing 40 µg/ml chloroquine diphosphate and Southern blotting. Faster migrating species are more positively supercoiled. The band at the top corresponds to nicked circular plasmid molecules, and the dots indicate the calculated centers of the gaussian distributions of topoisomers. B, linking number changes plotted as a function of time after hormone addition; each data point is derived from three independent experiments.
[View Larger Version of this Image (35K GIF file)]



DISCUSSION

Chromatin Perturbation Caused by Activation Domain Unmasking

In this paper we have used the yeast episomes TA17Delta 80 and TALS as reporters to monitor changes in chromatin structure caused by binding of GAL4 and GAL4·ER· VP16 in their activating and nonactivating configurations. The chromatin remodeling we have observed in both of these plasmids occurs outside the context of natural promoters. TALS (11) contains a single GAL4 binding site from the GAL3 promoter (UASg1 in Ref. 2) but lacks downstream promoter elements, including the TATA element and transcription start site. Furthermore, chromatin structure in TALS in yeast alpha  cells is dominated by the alpha 2 operator (11), and in the region perturbed by GAL4 and GAL4·ER·VP16, which corresponds to the region upstream of the GAL4 binding site in the GAL3 promoter, it is very different in TALS than in the endogenous GAL3 promoter whether GAL4 is present or absent.2 Thus, the results reported here suggest that the chromatin remodeling observed in natural promoters (2, 5-8) reflects a general property of at least some transcriptional activators that does not depend on collaboration of particular cis-acting promoter elements. The precise nature of the remodeling, however, depends on the chromatin structure that is perturbed. For example, substantial perturbation by GAL4 is seen with TALS and TA17Delta 80, both of which have nucleosomal GAL4 binding sites, but only modest perturbation is seen in the GAL1 promoter, in which the GAL4 binding sites are nonnucleosomal (5, 6).

The GAL4 binding site in TALS is located 33-49 base pairs from the edge of nucleosome IV, which is adjacent to the alpha 2·MCM1 nucleosome-positioning element (22). This region is inaccessible to E. coli Dam methyltransferase expressed in yeast (33). Nevertheless, the GAL4 DNA-binding domain can evidently gain access to this region, although whether it does so in the presence of a fully formed nucleosome or at a point in the cell cycle when nucleosome structure is perturbed, such as during DNA replication, has not been determined. Similarly, a GAL4 binding site near the center of nucleosome I of the TRP1ARS1 derivative TA17Delta 80 can be accessed by GAL4 (Ref. 10; Fig. 1), although this region is also inaccessible to E. coli Dam methyltransferase (33).

Some perturbation of the chromatin structure of TA17Delta 80 (Fig. 1) and TALS (Fig. 2) is caused by both GAL4 and GAL4·ER·VP16 in their nonactivating configurations, as evident by a slightly altered MNase digestion pattern. Binding by nonactivating GAL4·ER·VP16 and GAL4·ER is also demonstrated by interference with GAL4 activation (Tables I and III). This may represent transient or unstable binding under these conditions. It seems reasonable that some interaction must occur between the factor and its binding site even without an activation domain, since otherwise it is difficult to understand how the factor in its activating configuration makes its initial interaction (i.e. it seems unlikely that a single factor such as GAL4 would cause a global alteration in chromatin structure that allows the factor to interact with its binding sites in chromatin). Unmasking of the GAL4 activation domain by growth in galactose results in altered micrococcal nuclease cleavage of TALS chromatin, increased restriction enzyme accessibility to the SstI site in nucleosome IV, and a loss of negative superhelicity. The addition of hormone leads to similar changes mediated by GAL4·ER·VP16. Similarly, chromatin structure in TA17Delta 80 shows increased perturbation by GAL4 and GAL4·ER·VP16 in their activating compared with their nonactivating forms (Fig. 1; Ref. 10). The effect of hormone addition on TALS chromatin is not seen with GAL4·ER, showing that this effect is not a consequence of unmasking an occluded DNA-binding domain.

Two pathways by which GAL4 or GAL4·ER·VP16 could alter TALS chromatin structure in an activation domain-dependent manner are by increasing factor binding and by recruiting a chromatin remodeling activity. Increased or more stable binding could result in increased loss/perturbation of nucleosome IV in TALS and nucleosomes I and II in TA17Delta 80, because the GAL4 binding site is nucleosomal. This mechanism is suggested by experiments showing that occupancy of low and moderate affinity GAL4 binding sites is increased in the presence of a nearby TATA box in yeast, suggesting direct or indirect cooperative interactions between the GAL4 activation domain and TBP (45), and by in vivo footprinting data showing that an Oct-2 POU DNA-binding domain occupies binding sites in yeast more efficiently when it carries an activation domain (46). Similarly, GAL4 binding in mammalian cells is enhanced by the presence of an activation domain (47). This increased binding could be caused by an interaction between the activation domain and a protein or proteins involved in transcriptional activation, such as TBP, TFIIB, or the RNA polymerase II holoenzyme (48-50). The interacting protein could contact DNA sequences near the GAL4 binding site and increase the effective affinity of GAL4 through cooperative interactions. Both the interactions between the contacted protein(s) and DNA and the increased effective affinity of the activator for its site could inhibit histones from occupying these sequences and thereby alter chromatin structure. One possible difficulty with this mechanism is that chromatin remodeling in TALS occurs outside of the context of a natural promoter, and therefore, presumably, high affinity binding sites for components involved in transcription are lacking. A near consensus TATA box, TATATA, is present 330 base pairs from the UASGAL, distal to the alpha 2·MCM1 operator; however, activation domain-dependent changes in TALS chromatin structure are still observed when this sequence is mutated (data not shown). It is conceivable that nonspecific interactions between proteins recruited by the activation domain and sequences near the GAL4 binding site are sufficiently avid to increase GAL4 or GAL4·ER·VP16 binding. Since TBP has a high affinity for nonspecific sites in DNA (51) and interacts with the GAL4 (48, 50) and VP16 (49) activation domains in vitro, it remains a good candidate for such interactions.

This first mechanism does not involve any interactions specifically directed toward chromatin; rather, protein-DNA interactions are postulated to be sufficient to alter the ability of histones to occupy particular sequences. However, strong evidence exists for proteins that have evolved to contend with chromatin templates (52), and it is possible that an unmasked activation domain acts to recruit such proteins. For example, the GAL4 DNA binding domain has been shown to interact with ADA2 in vitro (48), which is part of a complex in yeast containing GCN5 (53). Since yeast GCN5 is homologous to Tetrahymena histone acetyltransferase A and itself possesses histone acetyltransferase activity (54), recruitment of the ADA·GCN5 complex could lead to alterations in chromatin structure. Another likely candidate for this role is the SWI·SNF complex (52), which in one in vitro study has been shown to cooperate with GAL4 derivatives to alter nucleosome structure and enhance GAL4 binding in a manner dependent on the strength of the activation domain attached to the GAL4 DNA-binding domain (55). It is of course also possible that both pathways contribute to the activation domain-dependent changes in chromatin structure we have reported here. For example, an activation domain may help basal transcription factors compete with histones for occupancy of sequences near the activator binding site (1), and this effect may also depend on auxiliary factors such as the SWI·SNF complex (56).

Whatever the mechanism by which the GAL4·ER·VP16 activation domain remodels chromatin, it is apparently able to do so in the absence of replication (Fig. 7). Chromatin remodeling by PHO4 (57), by the glucocorticoid receptor (58), and by the thyroid hormone receptor-retinoid X receptor heterodimer (8) also occurs independent of replication. The ability to remodel chromatin independent of replication may prove to be a general property of transcriptional activators.

Implications for the Mechanism of Hormone Activation of Estrogen Receptor

Our results suggest that GAL4·ER·VP16 can bind to a UASGAL in the absence of hormone, albeit weakly, but is still unable to activate transcription (Table I; Figs. 1 and 2). This suggests that the ER hormone-binding domain can mask activator function even when bound at a promoter, as also proposed for intact ER expressed in yeast (59) and mammalian cells (60). Remarkably, this occurs with a heterologous activation domain. Hormone administration induces substantial changes in chromatin structure, consistent with previous observations of hormone-induced alterations in chromatin structure mediated by ER derivatives expressed in yeast (44, 61). We suggest that upon hormone addition, unmasking the VP16 activation domain results in increased binding to chromatin or in recruitment of chromatin remodeling activity. An alternative explanation is that the unliganded hormone-binding domain of the ER partially masks the attached DNA-binding domain, as has been suggested for the intact ER (13, 44), and that hormone binding relieves this masking. However, if this were the case, the GAL4·ER chimera should have shown increased perturbation of chromatin upon hormone addition, and this was not observed.

Implications for Other Systems

As discussed in the introduction, activation domain-dependent perturbation of chromatin structure has been observed at the GAL1 and PHO5 promoters (2, 7). In both cases, perturbation is seen even when the TATA box is mutated. This could be explained by recruitment of factors that can modify chromatin components, as discussed above. It could also be explained by nonspecific interactions between TBP and DNA or by interactions between proteins recruited by the activation domain and sequences outside the TATA box. These latter interactions may be strong; Fedor and Kornberg (5) reported that coding sequences linked to the GAL1-10 promoter were transcribed under inducing conditions even in the absence of the GAL1 TATA and initiation sequences.

It has also been reported that PHO4 can bind to the nucleosomal site in the PHO5 promoter in the absence of the binding site located in the nearby linker region between nucleosomes (7, 62). This binding requires overexpression of PHO4 and requires PHO4 to carry an activation domain; it also results in disruption of all four positioned nucleosomes in the PHO5 promoter. This would again be consistent with an increased affinity of PHO4 for its binding site caused by recruitment of another DNA-binding protein by the PHO4 activation domain or by recruitment of chromatin-modifying machinery.

One important difference between the two mechanisms that we have suggested for activation domain-dependent chromatin remodeling is that one is passive in the sense that histones "get out of the way" as a consequence of binding of other factors (e.g. TBP or TFIIB), without invoking any special chromatin remodeling activity, whereas the second explicitly invokes such an activity. Determining what proteins are required for the activation domain-dependent changes in chromatin structure we have reported here should shed light on this problem and should also provide new insight into mechanisms of transcriptional activation in vivo.


FOOTNOTES

*   This work was supported in part by a New Investigator Award from the Wadsworth Center, New York State Department of Health, and by National Institutes of Health Grant GM51993 (to R. H. M.).The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
Dagger    To whom correspondence should be addressed: Tel.: 518-486-3116; Fax: 518-474-3181; E-mail: Randall.Morse{at}wadsworth.org.
1   The abbreviations used are: UAS, upstream activator sequence; MNase, micrococcal nuclease; ER, estrogen receptor.
2   M. Ryan and R. H. Morse, unpublished observations.

ACKNOWLEDGEMENTS

We thank Robert Simpson (National Institutes of Health) for generous support and encouragement, Michael Kladde for valuable discussions, Sharon Roth for a critical reading of the manuscript, and Rachael Jones and Peter Bocala for excellent technical help. Didier Picard, Michael Kladde, and Karen Arndt are thanked for providing strains and/or plasmids. We gratefully acknowledge the use of the Wadsworth Center's molecular genetics core facility.


REFERENCES

  1. Workman, J. L., Taylor, I. C. A., and Kingston, R. E. (1991) Cell 64, 533-544 [Medline] [Order article via Infotrieve]
  2. Axelrod, J. D., Reagan, M. S., and Majors, J. (1993) Genes & Dev. 7, 857-869 [Abstract]
  3. Hirschhorn, J. N., Brown, S. A., Clark, C. D., and Winston, F. (1992) Genes & Dev. 6, 2288-2298 [Abstract]
  4. Straka, C., and Horz, W. (1991) EMBO J. 10, 361-368 [Abstract]
  5. Fedor, M. J., and Kornberg, R. D. (1989) Mol. Cell. Biol. 9, 1721-1732 [Medline] [Order article via Infotrieve]
  6. Lohr, D., and Lopez, J. (1995) J. Biol. Chem. 270, 27671-27678 [Abstract/Free Full Text]
  7. Svaren, J., Schmitz, J., and Horz, W. (1994) EMBO J. 13, 4856-4862 [Abstract]
  8. Wong, J., Shi, Y.-B., and Wolffe, A. P. (1995) Genes & Dev. 9, 2696-2711 [Abstract]
  9. Fascher, K. D., Schmitz, J., and Horz, W. (1993) J. Mol. Biol. 231, 658-667 [CrossRef][Medline] [Order article via Infotrieve]
  10. Morse, R. H. (1993) Science 262, 1563-1566 [Medline] [Order article via Infotrieve]
  11. Roth, S. Y., Dean, A., and Simpson, R. T. (1990) Mol. Cell. Biol. 10, 2247-2260 [Medline] [Order article via Infotrieve]
  12. Bajwa, W., Torchia, T. E., and Hopper, J. E. (1988) Mol. Cell. Biol. 8, 3439-3447 [Medline] [Order article via Infotrieve]
  13. Kladde, M. P., Xu, M., and Simpson, R. T. (1996) EMBO J. 15, 6290-6300 [Abstract]
  14. Louvion, J.-F., Havaux-Copf, B., and Picard, D. (1993) Gene (Amst.) 131, 129-134 [CrossRef][Medline] [Order article via Infotrieve]
  15. Christianson, T. W., Sikorski, R. S., Dante, M., Shero, J. H., and Hieter, P. (1992) Gene (Amst.) 110, 119-122 [CrossRef][Medline] [Order article via Infotrieve]
  16. Fields, S., and Song, O. (1989) Nature 340, 245-246 [CrossRef][Medline] [Order article via Infotrieve]
  17. Winston, F., Dollard, C., and Ricupero-Hovasse, S. L. (1995) Yeast 11, 53-55 [Medline] [Order article via Infotrieve]
  18. Hill, J., Ian, K. A., Donald, G., and Griffiths, D. E. (1991) Nucleic Acids Res. 19, 5791 [Medline] [Order article via Infotrieve]
  19. Ito, H., Fukuda, Y., Marata, K., and Kimura, A. (1983) J. Bacteriol. 153, 163-168 [Medline] [Order article via Infotrieve]
  20. Miller, J. H. (1972) Experiments in Molecular Genetics, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY
  21. Rose, M. D., Winston, F., and Hieter, P. (1990) Methods in Yeast Genetics: A Laboratory Course Manual, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY
  22. Shimizu, M., Roth, S. Y., Szent-Gyorgyi, C., and Simpson, R. T. (1991) EMBO J. 10, 3033-3041 [Abstract]
  23. Fedor, M. J., Lue, N. F., and Kornberg, R. D. (1988) J. Mol. Biol. 204, 109-127 [Medline] [Order article via Infotrieve]
  24. Sambrook, J., Fritsch, E. F., and Maniatis, T. (1989) Molecular Cloning: A Laboratory Manual, 2nd Ed., Cold Spring Harbor Laboratory, Cold Spring Harbor, NY
  25. Nedospasov, S. A., and Georgiev, G. P. (1980) Biochem. Biophys. Res. Commun. 92, 532-539 [Medline] [Order article via Infotrieve]
  26. Wu, C. (1980) Nature 286, 854-860 [Medline] [Order article via Infotrieve]
  27. Church, G., and Gilbert, W. (1984) Proc. Natl. Acad. Sci. U. S. A. 81, 1991-1995 [Abstract]
  28. Morse, R. H. (1991) J. Mol. Biol. 222, 133-137 [Medline] [Order article via Infotrieve]
  29. Griggs, D. W., and Johnston, M. (1991) Proc. Natl. Acad. Sci. U. S. A. 88, 8597-8601 [Abstract]
  30. Simpson, R. T. (1991) Prog. Nucleic Acids Res. Mol. Biol. 40, 143-184 [Medline] [Order article via Infotrieve]
  31. Thoma, F. (1992) Biochim. Biophys. Acta 1130, 1-19 [Medline] [Order article via Infotrieve]
  32. Cooper, J. P., Roth, S. Y., and Simpson, R. T. (1994) Genes & Dev. 8, 1400-1410 [Abstract]
  33. Kladde, M. P., and Simpson, R. T. (1994) Proc. Natl. Acad. Sci. U. S. A. 91, 1361-1365 [Abstract]
  34. Johnston, S. A., Salmeron, J. M., Jr., and Dincher, S. S. (1987) Cell 50, 143-146 [Medline] [Order article via Infotrieve]
  35. Ma, J., and Ptashne, M. (1987) Cell 50, 137-142 [Medline] [Order article via Infotrieve]
  36. Giniger, E., Varnum, S. M., and Ptashne, M. (1985) Cell 40, 767-774 [Medline] [Order article via Infotrieve]
  37. Selleck, S. B., and Majors, J. (1987) Nature 325, 173-177 [CrossRef][Medline] [Order article via Infotrieve]
  38. Leuther, K. K., and Johnston, S. A. (1992) Science 256, 1333-1335 [Medline] [Order article via Infotrieve]
  39. Germond, J. E., Hirt, B., Oudet, P., Gross-Bellard, M., and Chambon, P. (1975) Proc. Natl. Acad. Sci. U. S. A. 72, 1843-1847 [Abstract]
  40. Simpson, R. T., Thoma, F., and Brubaker, J. M. (1985) Cell 42, 799-808 [Medline] [Order article via Infotrieve]
  41. Givens, R. M., Saavedra, R. A., and Huberman, J. A. (1996) J. Mol. Biol. 257, 53-65 [CrossRef][Medline] [Order article via Infotrieve]
  42. Saavedra, R. A., and Huberman, J. A. (1986) Cell 45, 65-70 [Medline] [Order article via Infotrieve]
  43. Francis, M. K., Phinney, D. G., and Ryder, K. (1995) J. Biol. Chem. 270, 11502-11513 [Abstract/Free Full Text]
  44. Gilbert, D. M., Losson, R., and Chambon, P. (1992) Nucleic Acids Res. 20, 4525-4531 [Abstract]
  45. Vashee, S., and Kodadek, T. (1995) Proc. Natl. Acad. Sci. U. S. A. 92, 10683-10687 [Abstract]
  46. Tanaka, M. (1996) Proc. Natl. Acad. Sci. U. S. A. 93, 4311-4315 [Abstract/Free Full Text]
  47. Bunker, C. A., and Kingston, R. E. (1996) Proc. Natl. Acad. U. S. A. 93, 10820-10825 [Abstract/Free Full Text]
  48. Melcher, K., and Johnston, S. A. (1995) Mol. Cell. Biol. 15, 2839-2848 [Abstract]
  49. Triezenberg, S. J. (1995) Current Opin. Genet. Dev. 5, 190-196 [CrossRef][Medline] [Order article via Infotrieve]
  50. Wu, Y., Reece, R. J., and Ptashne, M. (1996) EMBO J. 15, 3951-3963 [Abstract]
  51. Coleman, R. A., and Pugh, B. F. (1995) J. Biol. Chem. 270, 13850-13859 [Abstract/Free Full Text]
  52. Kingston, R. E., Bunker, C. A., and Imbalzano, A. N. (1996) Genes & Dev. 10, 905-920 [Abstract]
  53. Marcus, G. A., Silverman, N., Berger, S. L., Horiuchi, J., and Guarente, L. (1994) EMBO J. 13, 4807-4815 [Abstract]
  54. Brownell, J. E., Zhou, J., Ranalli, T., Kobayashi, R., Edmondson, D. G., Roth, S. Y., and Allis, C. D. (1996) Cell 84, 843-851 [Medline] [Order article via Infotrieve]
  55. Kwon, H., Imbalzano, A. N., Khavari, P. A., Kingston, R. E., and Green, M. R. (1994) Nature 370, 477-481 [CrossRef][Medline] [Order article via Infotrieve]
  56. Laurent, B. C., and Carlson, M. (1992) Genes & Dev. 6, 1707-1715 [Abstract]
  57. Schmid, A., Fascher, K.-D., and Horz, W. (1992) Cell 71, 853-864 [Medline] [Order article via Infotrieve]
  58. Reik, A., Schutz, G., and Stewart, A. F. (1991) EMBO J. 10, 2569-2576 [Abstract]
  59. McDonnell, D. P., Nawaz, Z., and O'Malley, B. W. (1991) Mol. Cell. Biol. 11, 4350-4355 [Medline] [Order article via Infotrieve]
  60. Reese, J. C., and Katzenellenbogen, B. S. (1992) Mol. Cell. Biol. 12, 4531-4538 [Abstract]
  61. Pham, T. A., Hwung, Y.-P., McDonnell, D. P., and O'Malley, B. W. (1991) J. Biol. Chem. 266, 18179-18187 [Abstract/Free Full Text]
  62. Venter, U., Svaren, J., Schmitz, J., Schmid, A., and Horz, W. (1994) EMBO J. 13, 4848-4855 [Abstract]

©1997 by The American Society for Biochemistry and Molecular Biology, Inc.